drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous genetically modified T cells expressing a chimeric antigen receptor targeting CD70, incorporating CD3ζ and costimulatory domains to activate, expand, secrete cytokines, and kill CD70-positive tumor cells after IV infusion.
nci_thesaurus_concept_id
C201176
nci_thesaurus_definition
Any preparation of chimeric antigen receptor (CAR) expressing T-lymphocytes that targets the tumor-associated antigen (TAA) CD70.
drug_mesh_term
T-Lymphocytes, Chimeric Antigen Receptor-Modified
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD70. Upon binding CD70 on tumor cells, the CAR’s CD3ζ and costimulatory domains activate the T cells, driving proliferation, cytokine release, and cytotoxic killing of CD70-positive cells via perforin/granzyme and death-receptor pathways.
drug_name
Anti-CD70 CAR-T cells
nct_id_drug_ref
NCT05990621